Abstract:Tuberculosis is remaining a global public health problem. The apperance and spread of multidrug-resistant and extensively drug-resistant tuberculosis is a big challenge for tuberculosis control. Antituberculosis drugs which were recommended by World Health Organization for treatment of drug-resistant tuberculosis have many shortcomings, such as less kinds, poor curative effects, serious adverse events and long treatment course. Therefore, it is urgent to develop drugs with new action. Bedaquiline, which is target ATP synthase of mycobacterium, is possessed of merits with unique mechanism, low resistance rate, long haf-life, high specificity, strong antibacterial activity, reduced treatment duration for multidrug-resistant tuberculosis, well safety and so on. At the same time, it has defects with high fatality rate which is diffcut to explain and the like. The artical mainly focus on the research progress of bedaquiline about its action and resistance mechanism, pharmacokinetics, antibacteria activity, clinic trials and safety in antituberculosis.
[1]Sotqiu G, Migliori GB. Facing multi-drug resistant tuberculosis[J]. Pulm Pharmacol Ther, 2014:1-5. DOI: 10.1016/j.pupt.2014.04.006 [2]Matteelli A, Carvalho AC, Dooley KE, et al. TMC207: the first compound of a new class of potent anti-tuberculosis drugs[J]. Future Microbiol, 2010, 5(6): 849-858. DOI: 10.2217/fmb.10.50 [3]Xiao HP. Bedaquiline for MDR-TB: WHO interim guidance and appliacation in China[C]. The 80th anniversary of antituberculosis association and 2013 national academic meeting, 2013: 17-21. (in Chinese) 肖和平. 贝达喹啉治疗MDR-TB WHO暂行指导原则和中国的应用[C]. 中国防痨协会80周年纪念暨2013年全国学术大会论文集, 2013:17-21. [4]Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of mycobacterium tuberculosis[J]. Science, 2005, 307: 223 -227. [5]Petrella S, Cambau E, Chauffour A, et al. Genetic basis for natural and acquired resistance of the diaryquinoline R207910 in mycobacteria[J]. Antimicrob Agents Chemother, 2006, 50(8): 2853-2856. DOI: 10.1128/AAC.00244-06 [6]Gupta S, Cohen KA, Winglee K, et al. Efflux inhibition with verapamil potentiates bedaquiline in mycobacterium tuberculosis[J]. Antimicrob Agents Chemother, 2014, 58: 574-576. DOI: 10.1128/ AAC.01462-13 [7]Andries K, Villellas C, Coeck N, et al. Acquired resistance of Mycobacterium tuberculosis to Bedaquiline[J]. PLoS One, 2014, 9(7): e102135. DOI: 10.1371/journal.pone.0102135 [8]US Food and Drug Administration. Briefing Package: NDA 204-384: Sirturo. 2012[EB/OL]. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM 329258.pdf, 2014-08-16/2014-10-04 [9]Liu K, Li F, Lu J, et al. Bedaquiline metabolism: enzymes and novel metabolites[J]. Drug Metab Dispos, 2014, 42(5): 863-866. DOI: 10.1124/dmd.113.056119 [10]Lounis N, Gevers T, Van Den Berg J, et al. Prevention of drug carryover effects in studies assessing antimycobacterial efficacy of TMC207[J]. J Clin Microbiol, 2008, 46(7): 2212-2215. DOI: 10.1128/ JCM.00177-08 [11]Huitric E, Verhasselt P, Andries K, et al. In vitro antimycobacterial spectrum of a diarylquinoline ATP-synthase inhibitor[J]. Antimicrob Agents Chemother, 2007, 51(11): 4202-4204. DOI: 10.1128/AAC.00181-07 [12]Koul A, Vranckx L, Dendouga N, et al. Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis[J]. J Biol Chem, 2008, 283(37): 25273-25280. DOI: 10.1074/jbc.M803899200 [13]Lounis N, Veziris N, Chauffour A, et al. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration[J]. Antimicrob Agents Chemother, 2006, 50(11): 3543-3547. DOI: 10.1128/AAC.00766-06 [14]Makarov V, Lechartier B, Zhang M, et al. Towards a new combination therapy for tuberculosis with next generation benzothiazinones[J]. EMBO Mol Med Mar, 2014, 6(3): 372-383. DOI: 10.1002/ emmm.201303575 [15]Ibrahim M, Truffot-Pernot C, Andries K, et al. Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis[J]. Am J ResPir Crit Care Med, 2009, 180(6): 553-557. DOI: 10.1164/rccm.200807-1152OC [16]Shang SB, Shanley CA, Caraway ML, et al. Activities of TMC207,rifampin,and pyrazinamide against mycobacterium tuberculosis infection in guinea pigs[J]. Antimicrob Agents Chemother, 2011, 55(1): 124-131. DOI: 10.1128/AAC.00978-10 [17]Andries K, Gevers T, Lounis N. Bactericidal potencies of new regimens are not predictive of their sterilizing potencies in a murine model of tuberculosis[J]. Antimicrob Agents Chemother, 2010, 54(11): 4540-4544. DOI: 10.1128/AAC.00934-10 [18]Ibrahim M, Andries K, Lounis N, et al. Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis[J]. Antimicrob Agents Chemother, 2007, 51(3): 1011-1015. DOI: 10.1128/AAC.00898-06 [19]Veziris N, Ibrahim M, Lounis N, et al. A once weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis[J]. Am J Respir Crit Care Med, 2009, 179(1): 75-79. DOI: 10.1164/rccm.200711-1736OC [20]Zhang T, Zhang M, Rosenthal IM, et al. Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection[J]. Am J Respir Crit Care Med, 2009, 180(11): 1151-1157. DOI: 10.1164/rccm.200905-0795OC [21]Zhang T, Li SY, Williams KN, et al. Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection[J]. Am J Respir Crit Care Med, 2011, 184(6): 732-737. DOI: 10.1164/rccm.201103-0397OC [22]Rustomjee R, Diacon AH, Allen J, et al. Early bactericidal activity and pharmacokinetics of the dairylquinoline TMC207 in treatment of pulmonary tuberculosis[J]. Antimicrob Agents Chemother, 2008, 52(8): 2831-2835. DOI: 10.1128/AAC.01204-07 [23] Koul A, Vranckx L, Dhar N, et al. Delayed bactericidal response of Mycobacterium tuberculosis to bedaquiline involves remodelling of bacterial metabolism[J]. Nat Commun, 2014, 5: 3369. DOI: 10.1038/ncomms4369 [24]Lounis N, Gevers T, Berg JVD, et al. Impact of the interaction of R207910 with rifampin on the treatment of tuberculosis studied in the mouse model[J]. Antimicrob Agents Chemother, 2008, 52(10): 3568-3572. DOI: 10.1128/AAC.00566-08 [25]Dooley KE, Park JG, Swindells S, et al. Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group study A5267[J]. J Acquir Immune Defic Syndr, 2012, 59(5): 455-462. DOI: 10.1097/ QAI.0b013e3182410503 [26]Diacon AH, Donald PR, Pym A, et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tubercolosis: longterm outcome, tolerability, and effect on emergence of drug resistance[J]. Antimicrob Agents Chemother, 2012, 56(6): 3271-3276. DOI: 10.1128 /AAC.06126-11